卡铂|T1058

Carboplatin
41575-94-4

￥1710 500mg 起订

￥974 200mg 起订

￥529 100mg 起订

上海更新日期：2024-12-02

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 卡铂

英文名称：: Carboplatin

CAS号：: 41575-94-4

品牌：: TargetMol

产地：: 美国

保存条件：: keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.72%

产品类别：: 抑制剂

货号：: T1058

Product Introduction

Bioactivity

名称	Carboplatin
描述	Carboplatin (JM-8) is a cisplatin derivative, a DNA synthesis inhibitor. Carboplatin binds to DNA, inhibits replication and transcription, and induces cell death. Carboplatin has antitumor activity.
细胞实验	3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. (Only for Reference)
激酶实验	Radioligand binding studies on human AT1 receptors: A radioligand binding assay is performed by using human AT1 receptor-coated microplates containing 4.4 to 6.2 fmol of receptors/well (10 μg of membrane protein/well). Membrane-coated wells are incubated with 45 μL of assay buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, and 0.005% CHAPS, pH 7.4) containing various concentrations of Azilsartan at room temperature. After 90 minutes, 5 μL of 125I-Sar1-Ile8-AII (final concentration 0.6 nM) dissolved in assay buffer is added to the wells, and the plate is incubated for 5 hours. In each step, the plate is briefly and gently shaken on a plate shaker. In washout experiments, the membranes are incubated with Azilsartan for 90 minutes, then immediately washed twice with 200 μL/well of assay buffer to remove unbound compounds, and further incubated for 5 hours with 125I-Sar1-Ile8-AII. Membrane-bound radioactivity is counted using a TopCount Microplate Scintillation and Luminescence Counter. In the experiments to estimate the dissociation rate of Azilsartan from AT1 receptors, membranes are incubated for 90 minutes with Azilsartan at a concentration of 30 nM for Azilsartan. Azilsartan inhibits the specific binding of 125I-Sar1-Ile8-AII to human AT1 by approximately 90%. The membranes are then immediately washed twice with 200 μL/well of assay buffer and further incubated with 125I-Sar1-Ile8-AII for 240 minutes. Membrane-bound radioactivity is counted using the TopCount Microplate Scintillation and Luminescence Counterat 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, or 240 minutes. Nonspecific binding of 125I-Sar1-Ile8-AII is estimated in the presence of 10 μM unlabeled AII. Unlabeled AII is added again after washout for the washout experiment. Specific binding is defined as total binding minus nonspecific binding.
体外活性	方法：5637 种细胞用 Carboplatin (0-10000 μM) 处理 4 h，使用 MTT 方法检测细胞活力。结果：Carboplatin 存在剂量依赖性的细胞杀伤作用，IC50 值为 289.3±2.90 μM。[1] 方法：人 RB 肿瘤细胞 Y79 用 Carboplatin (20-80 μg/mL) 处理 2 天，使用 Flow Cytometry 检测细胞凋亡情况。结果：Carboplatin 诱导细胞的早期凋亡率增加。[2]
体内活性	方法：为检测体内抗肿瘤活性，将 Carboplatin (20 mg/kg) 尾静脉注射给携带人 RB 肿瘤 Y79 的 BALB/c (nu/nu) 小鼠，每三天一次，持续一周或两周。结果：Carboplatin 在体内成功抑制人 RB 异种移植物的生长。[2] 方法：为检测体内抗肿瘤活性，将 Carboplatin (25-75 mg/kg) 腹腔注射给携带 EOC 异种移植瘤的免疫缺陷小鼠，每周一次，持续六周。结果：OV1946 和 OV4453 对 Carboplatin 敏感，OV90 和 OV4485 显示出中等反应，TOV21G 和 TOV112D 具有耐药性。[3]
存储条件	keep away from direct sunlight \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMF : 1 mg/mL (2.69 mM), Sonication is recommended. H2O : 12.5 mg/mL (33.67 mM), Sonication is recommended. (DMSO inactivates the activity of Carboplatin.)
关键字	inhibit \| JM8 \| Autophagy \| Carboplatin \| DNA Alkylator/Crosslinker \| NSC241240 \| JM 8 \| DNA/RNA Synthesis \| NSC-241240 \| Inhibitor
相关产品	Guanidine hydrochloride \| Naringin \| Valproic Acid \| Taurine \| Gefitinib \| Aceglutamide \| Hydroxychloroquine \| Curcumin \| Stavudine \| Thymidine \| Paeonol \| Sodium 4-phenylbutyrate
相关库	抗癌活性化合物库 \| 抗癌上市药物库 \| 肝脏毒性化合物库 \| 酪氨酸激酶分子库 \| 抗癌临床化合物库 \| 抗癌药物库

卡铂|||NSC 241240|||JM-8|||CBDCA|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子